BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 20302387)

  • 21. Histological and cytogenetic characterization of bone marrow in relation to prognosis and diagnosis of myelodysplastic syndromes.
    Sakuma T; Hayashi Y; Kanomata N; Murayama T; Matsui T; Kajimoto K; Hanioka K; Chihara K; Maeda S
    Pathol Int; 2006 Apr; 56(4):191-9. PubMed ID: 16634964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differences in the distribution of subtypes according to the WHO classification 2008 between Japanese and German patients with refractory anemia according to the FAB classification in myelodysplastic syndromes.
    Matsuda A; Germing U; Jinnai I; Araseki K; Kuendgen A; Strupp C; Iwanaga M; Miyazaki Y; Hata T; Bessho M; Gattermann N; Tomonaga M
    Leuk Res; 2010 Aug; 34(8):974-80. PubMed ID: 20022110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunologic characteristics and prognosis of myelodysplastic syndrome new subtype: refractory anemia with excess blasts-II.
    Wei J; Zhou XF; Zhao F; Zhou JF; Chen Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):111-6. PubMed ID: 19236759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The application of a new prognostic score system for 435 cases of primary myelodysplastic syndrome diagnosed with WHO classification].
    Wang XQ;
    Zhonghua Nei Ke Za Zhi; 2009 Aug; 48(8):633-7. PubMed ID: 19954053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).
    Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Blanco ML; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu M; Ferrer A; Sanz GF; Florensa L
    Am J Hematol; 2017 Jul; 92(7):614-621. PubMed ID: 28370234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of risk groups in myelodysplastic syndromes. A multicenter study.
    Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I
    Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes.
    Molldrem JJ; Leifer E; Bahceci E; Saunthararajah Y; Rivera M; Dunbar C; Liu J; Nakamura R; Young NS; Barrett AJ
    Ann Intern Med; 2002 Aug; 137(3):156-63. PubMed ID: 12160363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The clinical, haematological and morphological profile of patients with myelodysplastic syndromes: a single institution experience from Turkey.
    Demirkan F; Alacacioglu I; Piskin O; Ozsan HG; Akinci B; Ozcan AM; Yavuzsen T; Yuksel E; Undar B
    Leuk Lymphoma; 2007 Jul; 48(7):1372-8. PubMed ID: 17613766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
    Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
    Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification.
    Font P; Loscertales J; Benavente C; Bermejo A; Callejas M; Garcia-Alonso L; Garcia-Marcilla A; Gil S; Lopez-Rubio M; Martin E; Muñoz C; Ricard P; Soto C; Balsalobre P; Villegas A
    Ann Hematol; 2013 Jan; 92(1):19-24. PubMed ID: 22948274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytogenetic features and prognosis analysis in Chinese patients with myelodysplastic syndrome: a multicenter study.
    Wang H; Wang X; Xu X; Lin G
    Ann Hematol; 2010 Jun; 89(6):535-44. PubMed ID: 19921190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined stratification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patients who may benefit from stem cell transplantation.
    Cermák J; Vítek A; Michalová K
    Leuk Res; 2004 Jun; 28(6):551-7. PubMed ID: 15120930
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The presence of clonal cell subpopulations in peripheral blood and bone marrow of patients with refractory cytopenia with multilineage dysplasia but not in patients with refractory anemia may reflect a multistep pathogenesis of myelodysplasia.
    Cermák J; Belicková M; Krejcová H; Michalová K; Zilovcová S; Zemanová Z; Brezinová J; Sieglová Z
    Leuk Res; 2005 Apr; 29(4):371-9. PubMed ID: 15725470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases.
    Bourgeois E; Caulier MT; Rose C; Dupriez B; Bauters F; Fenaux P
    Leukemia; 2001 Jun; 15(6):950-3. PubMed ID: 11417482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of some clinical, morphological and cytogenetic findings in refractory anaemia (RA) and RA with sideroblasts.
    Kerndrup G; Pedersen B; Ellegaard J; Hokland P
    Blut; 1986 Jan; 52(1):35-43. PubMed ID: 3455830
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome.
    Knipp S; Strupp C; Gattermann N; Hildebrandt B; Schapira M; Giagounidis A; Aul C; Haas R; Germing U
    Leuk Res; 2008 Jan; 32(1):33-7. PubMed ID: 17412418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Analysis on laboratory and clinical characteristics in 65 cases of myelodysplastic syndrome].
    Chen BA; Gao C; Ding J; Ding JH; Sun YY; Zhao G; Cheng J; Wang J; Bao W; Song HH; Xia GH; Ma JL; Wu LL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1472-6. PubMed ID: 20030929
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In patients with myelodysplastic syndromes with del(5q), factors other than age and sex contribute to the prognostic advantage, which diminishes over time.
    Lauseker M; Schemenau J; Strupp C; Kündgen A; Gattermann N; Hasford J; Germing U
    Br J Haematol; 2015 Sep; 170(5):687-93. PubMed ID: 25960152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal.
    Breccia M; Latagliata R; Cannella L; Carmosino I; De Cuia R; Frustaci A; Stefanizzi C; Santopietro M; Alimena G
    Leuk Res; 2009 Mar; 33(3):391-4. PubMed ID: 18676015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Myelodisplasic syndromes diagnosed in a geriatric hospital: morphological profile in 100 patients].
    Dewulf G; Gouin I; Pautas E; Gaussem P; Chaïbi P; Andreux JP; Siguret V
    Ann Biol Clin (Paris); 2004; 62(2):197-202. PubMed ID: 15047472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.